Printed From:

Healthcare professionals have chosen Lantus® for over 18 years1

DEMONSTRATED LONG-TERM CV SAFETY DATA IN THE LANDMARK ORIGIN TRIAL1-3*

Including CV death, nonfatal MI, nonfatal stroke, revascularization, or hospitalization for heart failure.

CV Evaluation from the ORIGIN Trial over 6.2 Years (N=12,537)

No statistically significant differences between Lantus® and standard care in the co-primary endpoints

Mean A1C over 6.2 years (median)

Safety results

Study Design

A randomized study of patients with IFG and/or IGT or early type 2 diabetes mellitus and established CV disease or CV risk at baseline. Patients received either Lantus® (n=6264) titrated to a target FPG of ≤95 mg/dL or standard care (n=6273). Standard care patients remained on their original treatment, if applicable, at randomization. Additional agents could be added as needed at the discretion of the investigator. The co-primary outcomes were nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and these events plus revascularization or hospitalization for heart failure. Microvascular outcomes, incident diabetes, hypoglycemia, weight, and cancers were also compared between groups. Median follow-up: 6.2 years.